PubMed Health⌕ Search

Biomedical subjects

L X Cubeddu

Publications and source records attributed to L X Cubeddu.

At least 55 records · Page 3Linked to original sources
PubMed1992

Mechanisms by which cancer chemotherapeutic drugs induce emesis.

Because the area postrema seems essential for chemotherapy-induced vomiting, both circulating and/or neurally mediated stimuli in this area could trigger the emetic response. In our laboratories results of cross-circulation and direct intracerebroventricular infusion experiments in dogs do not support a role for circulating substances. The large increases in serum vasopressin induced by cisplatin were not blocked by inhibitors of the angiotensin-converting enzyme. In the ferret inhibition of serotonin synthesis with p-chloro-phenylalanine, administration of selective antagonists of 5-hydroxy-tryptamine3 (5-HT3) receptors, or visceral deafferentation inhibited the emetic response evoked by cisplatin or high-dose cyclophosphamide. The results suggest that serotonin plays an important role and that peripheral neural mechanisms are involved in the emetic response. The strong antiemetic efficacy of selective 5-HT3 antagonists also has been confirmed in humans. In cancer patients high-dose cisplatin increased the plasma and urinary levels of 5-hydroxy-indoleacetic acid (5-HIAA), but did not affect platelet and free plasma serotonin. The changes in 5-HIAA levels paralleled the onset and development of vomiting. No evidence of serotonin depletion has been obtained after high-dose cisplatin. Dacarbazine, another strongly emetogenic agent, increased urinary 5-HIAA; however, only small increases in 5-HIAA were produced with low-dose cisplatin or cyclophosphamide-containing regimens. Thus, emetogenicity appears to be directly related to the ability of the cytotoxic agent to release serotonin. In humans, antiemetics such as ondansetron, metoclopramide, and dexamethasone did not effect high-dose cisplatin-induced increases in serotonin metabolism. Therefore, these antiemetics seem not to affect the amount of serotonin released. The mechanism by which chemotherapeutic drugs induce serotonin release is unknown; however, release may occur by direct cytotoxicity on the gastrointestinal mucosa, including the enterochromaffin cells. Delayed emesis appears to be mediated by 5-HT3-independent mechanisms. It is proposed that emesis that develops despite high-dose ondansetron (residual emesis) should be considered delayed emesis. Residual and delayed episodes of emesis have similar time courses, are characterized by very mild emetic episodes and poor response to 5-HT3 antagonists, and are not associated with increases in serotonin metabolism.

Animals↗
PubMed1992

Comparative effects of verapamil and volume overload on atrial natriuretic factors and the renin-angiotensin aldosterone-vasopressin system.

The authors compared the effects of verapamil (120 mg three times daily for 3 days) with those of acute volume expansion with normal saline on the plasma levels of atrial natriuretic factors (ANF), renin (PRA), angiotensin II (AII), aldosterone (ALD), and arginine-vasopressin (AVP) in healthy subjects. A randomized, double-blind, placebo-controlled study of crossover design was employed, where each individual received two acute volume overloads 1 week apart, one during placebo and the other during treatment with verapamil. Verapamil reduced blood pressure (BP) and increased the plasma levels of ANF, PRA, AII, ALD, and AVP. Strong positive correlations were observed between PRA, AII, ALD, and AVP, but not with ANF. Acute volume expansion (1500 mL saline in 15 minutes, in supine legs-up position) similarly to verapamil increased ANF levels; however, opposite to verapamil, it reduced PRA-AII-ALD, did not modify AVP levels, and increased BP. The mechanisms of these changes are discussed. In verapamil-treated subjects, volume expansion produced an additional increase in ANF and inhibited the PRA-AII-ALD axis, suggesting that in young healthy individuals, verapamil does not interfere with the reflex compensatory hormonal mechanisms activated under circumstances of acute volume-salt overload, with rapid expansion of the central vascular compartment. Our study indicates that verapamil and volume expansion represent two different stimuli for ANF secretion associated with opposite changes in the PRA-AII-ALD axis. In addition, verapamil can be used as a tool to study and understand the simultaneous increases in ANF and in PRA, AII, and AVP, characteristics of congestive heart failure.

Adult↗
PubMed1991

Carbachol-phorbol ester interactions at muscarinic receptors modulating dopamine release from rabbit striatal slices.

Both 4-beta-12,13-dibutyrate phorbol-ester (PDBu) (EC50% = 82 +/- 12 nM) and carbachol (EC50% = 2.3 +/- 0.3.5 microM) enhanced dopamine (DA) release from rabbit striatal slices. No additivity was observed when slices were treated simultaneously with 0.1 microM PDBu and 10 microM carbachol. Pretreatment with PDBu (0.01-0.1 microM) abolished carbachol-induced facilitation of DA release. Pretreatment with carbachol (3-100 microM) antagonized the enhancement in DA release produced by PDBu. The effect of carbachol was blocked by atropine (0.1 microM) and not by hexamethonium (10 microM). The effect of PDBu was not modified by the acetylcholine receptor (AChR) antagonists. If muscarinic (MAChR) MAChR were blocked by atropine (0.1 microM), pretreatment with carbachol failed to antagonize PDBu-induced facilitation of DA release. This is the first report to indicate that activation of M1-MAChR by an agonist prevents the effects of an active phorbol-ester. We suggest that activation of M1-MAChR enhances DA release possibly through activation of PKC.

Animals↗
PubMed1990

Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting.

We compared the efficacy and safety of ondansetron (GR 38032F), a selective antagonist of serotonin S3 receptors, with that of placebo in controlling the nausea and vomiting induced by cisplatin treatment in 28 patients with cancer. The patients received either three intravenous doses of ondansetron (0.15 mg per kilogram of body weight) or normal saline (placebo) at four-hour intervals, beginning 30 minutes before the administration of cisplatin. Nausea and vomiting were markedly diminished in the group given ondansetron. The median time to the first episode of emesis was 2.8 hours in the placebo group and 11.6 hours in the ondansetron group (P less than 0.001); the median number of episodes in 24 hours was 5.5 in the placebo group and 1.5 in the ondansetron group (P less than 0.001); the mean (+/- SEM) number of regurgitations or dry heaves per episode was 3.2 +/- 0.5 in the placebo group and 1.17 +/- 0.1 in the ondansetron group (P less than 0.001). None of the 14 patients given ondansetron, but 12 of 14 given placebo, required treatment with antiemetic-rescue agents for the control of nausea and vomiting. There were no adverse effects attributable to ondansetron. The urinary excretion of 5-hydroxyindoleacetic acid, the main metabolite of serotonin, was increased in all patients two to six hours after they received cisplatin chemotherapy, and the increases paralleled the episodes of emesis. We conclude that ondansetron is an effective and safe agent for controlling the nausea and vomiting induced by cisplatin treatment. We suggest that cisplatin treatment increases the release of serotonin from enterochromaffin cells, and that ondansetron acts by blocking S3 receptors for serotonin.

Adult↗
PubMed1990

Role of angiotensin II and vasopressin in cisplatin-induced emesis.

Cisplatin-containing chemotherapy regimens are known to produce intense nausea and vomiting. Angiotensin II (AII) and vasopressin (AVP) have been shown to have emetic properties. The role of these two peptides on cisplatin-induced vomiting was investigated in beagle dogs. Cisplatin (2 mg/kg, IV over 5 min) produced consistent emesis in all dogs after a mean latency time of 144 +/- 4 min. Serum Angiotensin Converting Enzyme (ACE) and plasma AII levels did not significantly change 3 hr after cisplatin administration (at the time of nausea and emesis) in control animals. AVP levels rose from 0.3 pg/ml to 7.5 pg/ml 3 hrs after cisplatin. Complete inhibition of ACE with enalapril (given at 3 mg/kg p.o., 3 hrs prior to cisplatin) reduced AII levels by 70%, but failed to significantly modify the increase in AVP levels (7.2 +/- 2.2 pg/ml), the latency time to emesis (149 +/- 2 min) and the number of emetic episodes induced by cisplatin. These results suggest that AII does not mediate cisplatin-induced emesis, nor does it mediate the increase in AVP observed at the time of emesis. We propose that AVP may be a good marker for nausea and emesis, and that increases in AVP may be neurally-mediated. The large increase in circulating AVP may represent a desirable water conservation response in anticipation of fluid losses induced by vomiting.

Angiotensin II↗
PubMed1990

Is the release of dopamine from medial prefrontal cortex modulated by presynaptic receptors? Comparison with nigrostriatal and mesolimbic terminals.

Results obtained from our in vitro studies employing superfused slices obtained from three functionally different brain regions rich in DA axon terminals were discussed. Striking qualitative and quantitative similarities were found for the modulation of DA release from the nucleus caudate and the OT of the rabbit. However, the PFC DA terminals showed important differences from the nigrostriatal and mesolimbic DA terminals. Although release modulatory D2 DA autoreceptors could also be demonstrated in superfused slices of the PFC, our results suggest that the cortical nerve terminals may have a lower number of functional autoreceptors or a reduced efficiency of coupling between receptors and inhibition of release. Either possibility could explain (a) the poor inhibitory efficacy of the agonists, (b) the small facilitatory effect of the antagonists, (c) the disproportionate increase in transmitter overflow produced by neuronal uptake inhibitors, and (d) the lack of synergism between uptake inhibitors and DA antagonists. When the efficacy of the autoreceptor mechanisms was evaluated at stimulation frequencies comparable to the in vivo firing rates reported for each of the three neuronal groups, it was found that DA release from the striatum and the OT was tightly modulated by presynaptic D2 DA receptors; whereas release from PFC was not. We propose that the autoreceptor-mediated control of DA release from PFC may not function in vivo, even though modulation of release by presynaptic D2 DA receptors from PFC terminals could be demonstrated under specific experimental conditions in vitro. However, it is envisaged that if in vivo firing rate of the PFC DA neurons is reduced, the inhibitory actions of DA agonists on DA release may be regained. From these and other studies it is apparent that drug effects on autoreceptors are highly dependent on the rate and duration of stimulation applied to a specific neuronal group. We propose that the basal status of activity of a specific neuronal target could determine the type and magnitude of the effect produced by a therapeutic agent acting at release modulatory receptors. The neuronal activity (firing rate and pattern) may be affected by physiological status, disease, and by current or previous drug treatments. The mechanisms by which PFC DA terminals release a larger proportion of their storage pool compared to other mesotelencephalic DA terminals is unknown and may represent a compensatory mechanism to the continuous rapid firing rates at which these neurons are exposed in vivo.(ABSTRACT TRUNCATED AT 400 WORDS)

Animals↗
PubMed1990

Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens.

The control of nausea and emesis in cancer patients receiving chemotherapy poses a significant management problem. In this randomized, double-blind, placebo-controlled study, we evaluated the effect of serotonin S3 receptor blockade with ondansetron (GR 38032F) on the prevention of nausea and vomiting induced by cyclophosphamide-containing chemotherapy. Cyclophosphamide was given in doses of 500 to 600 mg/m2 and ondansetron as three intravenous (IV) doses of 0.15 mg/kg. Most patients had breast cancer. Cyclophosphamide was given in combination with doxorubicin (65% of patients) or with fluorouracil (85% of patients: 50% with Adriamycin [doxorubicin; Adria Laboratories, Columbus, OH] and 35% with methotrexate). All placebo-treated patients experienced vomiting, whereas 70% of patients treated with ondansetron did not vomit (P = .008). Median nausea scores were 8 mm on ondansetron and 65 mm on placebo (P less than .001). Seventy percent of patients treated with ondansetron retained their normal appetite, compared with 10% of placebo patients. Adverse events occurred in six placebo patients and one ondansetron patient. Diarrhea and headache were the most common events, both occurring more frequently in the placebo group. There were no extrapyramidal reactions, and the only significant biochemical change occurred in a placebo-treated patient. These results suggest that serotonin S3 receptor antagonists represent a novel, effective, and safe mode of therapy for nausea and emesis induced by cyclophosphamide-containing chemotherapies. In addition, our observations are compatible with the view that serotonin, acting on S3 receptors, mediates the nausea and emesis occurring after cyclophosphamide chemotherapy.

Adult↗
PubMed1990

Neurotensin-induced dopamine release in vivo and in vitro from substantia nigra and nucleus caudate.

We compared the dopamine (DA) releasing effects of neurotensin (NT) from cell bodies (substantia nigra) and nerve terminals (nucleus caudate). In rats implanted with push-pull cannula, NT induced DA release from substantia nigra and nucleus caudate. NT was more potent in releasing DA from the substantia nigra than from the nucleus caudate (EC50%, 1.1 microM in substantia nigra and 9.8 microM in nucleus caudate). In vitro, in superfused rabbit brain slices, NT enhanced the depolarization-evoked release of DA and exerted a direct releasing effect. The latter was greater in the substantia nigra, and the former in the nucleus caudate. The direct releasing effect of NT was not inhibited, but enhanced by nomifensine (3 microM). Sulpiride, a D2 DA receptor antagonist, failed to modify NT-induced DA release; in addition, NT did not affect the inhibition of DA and acetylcholine release produced by LY-171555, a D2 DA agonist. In both the substantia nigra and the nucleus caudate, desensitization to the releasing effect of NT was observed, either after 2.5, 5, or 10 min of exposure to the peptide. A synergistic interaction on DA release was observed between NT and potassium (K+), and between NT and electrical stimulation. Greater synergism was observed with high extracellular K+. Pretreatment of striatal slices with 15 mM K+ produced a 9-fold enhancement of NT-induced DA release. When K+ (25 mM, 2 min) was given together with NT there was a 2- to 3-fold increase in DA release compared to the release evoked by K+ in the absence of NT.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗
PubMed1990

Thermodynamic analyses of the binding of substrates and uptake inhibitors on the neuronal carrier of dopamine labeled with [3H]GBR 12783 or [3H]mazindol.

We have investigated the thermodynamic properties of the binding of substrates and uptake blockers to the specific sites labeled with a tritiated dopamine uptake inhibitor (i.e., 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenyl-2-propenyl)piperazine ([3H] GBR 12783) or [3H]mazindol) using striatal membrane preparations. Raising the incubation temperature from 0 degrees C to 25 degrees C or 37 degrees C resulted in an increase in the dissociation constant of both [3H]mazindol and [3H]GBR 12783 for their specific sites of binding present in membrane suspensions obtained from either rabbit or rat striatum. However, maximal concentrations of binding sites were not affected by temperature. At all tested temperatures, both substrates and carrier blockers competed with either [3H]mazindol or [3H]GBR 12783 in a monophasic fashion, with Hill coefficients close to unity. Raising the temperature induced little or no increase in inhibition constants (Ki) for substrates (Ki ratio 37/0 degrees C less than 2.5). This is consistent with the mild increase of the Michaelis constant of dopamine for the neuronal uptake system when the incubation temperature was raised from 12.5 to 37 degrees C (from 126 to 406 nM). In contrast, increasing the temperature resulted in a more important increase in the Ki of uptake inhibitors (33 greater than Ki ratio greater than 5). Thermodynamic calculations showed that the binding of substrates is generally characterized by a mild decrease in enthalpy (range, -2- -6 kcal/mol) associated with an increase in entropy, whereas binding of uptake inhibitors led to a decrease of both parameters.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗
PubMed1990

Rapid desensitization of dopamine release induced by neurotensin and neurotensin fragments.

Neurotensin (NT), a tridecapeptide, induced a concentration-dependent release of dopamine (DA) from the striatum. In addition, NT8-13 and Nacetyl-NT8-13, the carboxy-terminal-containing hexapeptides, were much more effective as DA releasers than the amino-terminal, NT1-6 peptide. The potency and efficacy of NT in inducing DA release was markedly enhanced by increases in the extracellular concentration of potassium (K+). Similar to electrical stimulation and to elevated extracellular K+, NT-induced DA release was inhibited by 70% in the presence of 0.13 mM calcium. Desensitization to NT was observed after a first exposure to NT for 2.5 to 10 min, despite a 20- to 85-min washout period between exposures, with NT-free medium. The loss of response was not due to degradation or inactivation of the peptide, nor it was due to activation of DA autoreceptors or the DA transporter. NT-induced desensitization was not associated to a loss of responsiveness to DA release elicited by electrical stimulation or by high K+. In addition, desensitization occurred even if NT-induced DA release was markedly enhanced by high extracellular K+ (10 and 15 mM). Inhibition of NT-induced DA release by low calcium (on the first exposure) did not prevent the development of desensitization. Similar to the parent peptide, desensitization was observed with the active carboxy-terminal NT fragments. However, a first exposure to NT1-6 did not induce desensitization to NT8-13. These results are compatible with the view that NT-induced DA release and the development of desensitization are mediated through an action of NT on NT receptors.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗
PubMed1989

Comparative efficacy, safety, and kinetics of immediate- and slow-release verapamil in hispanic patients with essential hypertension.

We assessed the pharmacokinetics and pharmacodynamics of immediate-release (IR) and slow-release (SR) verapamil in Hispanic patients with mild to moderate essential hypertension. Area under the curve and Cmax increased linearly with the dose of IR and SR. Plasma levels showed a more gradual increase and were maintained elevated for longer periods with SR. Both IR and SR reduced blood pressure (BP) significantly. Peak BP reduction with 240 mg q.i.d. SR (6 h postdose) or 80 mg t.i.d. IR (4 h postdose) averaged 28/18 and 23/20 mm Hg, respectively. Morning predose BP levels were reduced 16/5 mm Hg by SR and 5/6 mm Hg by IR. Peak PR prolongation averaged 43 ms for SR and 56 ms with IR. Heart rate was not modified. With 480 mg/day there was a greater BP reduction with no relevant changes in HR and no further increases in PR intervals. However, incidence of side effects (headaches, dizziness) was enhanced with 480 mg/day IR but not with SR. These results suggest that Hispanic patients have a good response to verapamil. The pharmacokinetic characteristics of SR verapamil account for its more favorable side-effect profile observed with this formulation. SR is considered advantageous to IR for the chronic treatment of hypertensive patients.

Adult↗
PubMed1989

Effects of low extracellular chloride on dopamine release and the dopamine transporter.

Removal of chloride (Cl-) from the superfusion medium results in increased spontaneous efflux of dopamine (DA) but not acetylcholine from rabbit striatal slices prelabeled with [3H]DA and [14C]choline. Cl- was substituted to varying degrees with the impermeant anion, isethionate (IS-), or the permeant anion, nitrate (NO3-). The magnitude of low Cl(-)-induced DA efflux was inversely related to the external [Cl-] and was greater with IS- than with NO3-. Analysis of the composition of the 3H efflux in terms of DA and its metabolites revealed an increase in [3H]DA with decreasing Cl- concentration. Reduction of external Ca++ from 1.3 to 0.13 mM increased low Cl(-)-induced DA efflux. In slices depleted of vesicular DA by reserpine pretreatment and subsequently labeled and superfused in the presence of monoamine oxidase and catechol-O-methyltransferase inhibitors, the same inverse relationship between [Cl-] and spontaneous DA efflux was observed. Neuronal DA uptake inhibitors, nomifensine, mazindol, GBR-12909 and cocaine, all increased the rate of low Cl(-)-induced DA efflux in the reserpinized preparation. Cl(-)-induced DA efflux in untreated and reserpinized preparations was not blocked by tetrodotoxin, amiloride, furosemide, picrotoxin or 4-acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic acid). Low Cl- inhibited initial rates of [3H]DA uptake. At Cl- concentrations producing significantly different efflux rates (0 and 7.4 mM Cl-, IS- and NO3- substitution), DA uptake was inhibited in all cases by greater than 90%. Additionally, the binding of [3H]mazindol, one of the uptake inhibitors, to striatal membranes was unaffected by removal of Cl-. In summary, low Cl- produces a nonexocytotic rapid outward transport of DA. Extracellular Cl- is not required for the binding to transporter sites or for the inhibition of neuronal uptake produced by neuronal uptake inhibitors.

Acetylcholine↗
PubMed1989

Phorbol esters and D2-dopamine receptors.

4-beta-Phorbol-12,13-dibutyrate (PDBu), a powerful activator of protein kinase C (PKC), enhanced dopamine (DA) release evoked by electrical stimulation (1 Hz, 2 min) from the striatum and the prefrontal cortex of the rabbit. However, acetylcholine (ACh) release from the striatum (1 Hz, 2 min), was only enhanced slightly by PDBu. The increase in DA release induced by PDBu was reduced markedly at higher frequencies of stimulation. Sulpiride (10 microM) alone, a D2 DA-receptor antagonist, or combined with nomifensine (3 microM), a neuronal-uptake inhibitor, did not prevent PDBu-induced facilitation of DA release from prefrontal cortex or striatum. The D2 DA agonists (LY-171555, bromocriptine and apomorphine) inhibited in a concentration-dependent manner the stimulation-evoked overflow of DA and ACh from the striatum, and of DA from the prefrontal cortex. Pretreatment with PDBu antagonized the inhibitory effect of the three agonists on DA and ACh release. A reduction both in Emax and IC50 was observed in PDBu-treated slices. Removal of endogenous DA by pretreatment with reserpine and alpha-methyl-p-tyrosine, failed to prevent PDBu-induced antagonism of apomorphine effects on ACh release, indicating that the antagonism of agonist effects was not due to higher synaptic levels of endogenous DA. The inactive enantiomer of PDBu, 4-alpha-12,13-dibutyrate did not enhance DA release and failed to modify the effects of D2 agonists on DA release.(ABSTRACT TRUNCATED AT 250 WORDS)

Acetylcholine↗
PubMed1989

Differential effects of phorbol ester on prefrontal cortex and striatal dopamine terminals: dependence on rate and duration of stimulation.

Compared to the nigrostriatal dopamine (DA) neurons, the mesocortical DA neurons projecting to the prefrontal cortex (PFC) are able to sustain higher levels of release when driven at high stimulation frequencies. The effect of a well known activator of protein kinase C (PKC), 4-beta-phorbol-12, 13-dibutyrate (PDBu), were compared on PFC and striatal DA terminals. DA release was monitored from slices of the rabbit PFC and striatum obtained from the same animal. The PKC activator, PDBu (30-1000 nM) enhanced the stimulation-evoked release (SER) of DA from PFC and striatum. The magnitude of the facilitation of DA release produced by PDBu was much greater from the PFC than from the striatum. In the striatum, PDBu produced a bell-shaped dose-response curve, i.e., 0.03 and 1 microM PDBu enhanced SER of DA by 25%, whereas 0.1 and 0.3 microM PDBu enhanced DA release by 60 and 100%, respectively (1 Hz, 120 pulses). In the PFC, 0.03 microM enhanced the SER of DA by 70% and 1 microM by 250% (1 Hz, 120 pulses). In addition, in the PFC, PDBu enhance the basal release of DA (+65% at 1 microM); this effect was not seen in the striatum. The inactive isomer, 4-alpha-phorbol-12, 13-dibutyrate (0.03-1 microM) failed to increase the SER and the basal release of DA from PFC or striatum. The SER of DA was dependent on the rate and duration of stimulation. However, under all conditions of stimulation studied DA release from PFC was always greater than from the striatum.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗
PubMed1989

Comparative antidopaminergic properties of thioridazine, mesoridazine and sulforidazine on the corpus striatum.

The functional antidopaminergic potencies of the atypical antipsychotic drug thioridazine (THD), as well as its active metabolites mesoridazine (MES) and sulforidazine (SUL), were assessed by testing their blockade of the inhibitory effects of endogenous dopamine (DA) or apomorphine on the electrically evoked release of radiolabeled DA and acetylcholine (ACh) from perfused rabbit striatal slices. These functional comparisons (reflecting presynaptic and postsynaptic DA receptors, respectively) were correlated with potency estimations of these drugs in competing for D2 DA receptors (i.e., [3H]spiperone binding sites) in rabbit striatal homogenates. Similar orders of potency (SUL greater than MES much greater than THD) were found for blockade of pre- and postsynaptic DA receptors modulating DA and ACh release, respectively, as well as in competing for [3H]spiperone binding sites in the striatum. MES, SUL and haloperidol were 2 to 3 times more potent at DA release modulatory receptors than postsynaptic DA receptors. In contrast, THD was 8 times more potent at antagonizing the apomorphine-induced inhibition of DA release than against apomorphine's effect on ACh release. THD was virtually inactive in antagonizing the inhibition of ACh release induced when nomifensine was used to increase endogenous synaptic DA, despite significantly antagonizing these effects on DA release in the same slices. Together, these data indicate that: 1) MES and SUL are responsible for a significant part of the antidopaminergic effects attributed to THD; 2) THD should produce less cholinergic activation than other neuroleptics; and 3) that nonreceptor-mediated effects at high THD concentrations may mask effects due to receptor blockade.

Acetylcholine↗
PubMed1989

Comparative anticholinergic properties of thioridazine, mesoridazine and sulforidazine.

The anticholinergic properties of thioridazine (THD) and its metabolites mesoridazine (MES) and sulforidazine (SUL) were compared to the antimuscarinics atropine and quinuclidinylbenzilate (QNB). THD, MES and SUL were virtually inactive in antagonizing the carbachol-induced inhibition of evoked ACh release from perfused rabbit striatal slices. This lack of effect was seen even when dopamine influences were abolished by treatment with reserpine and alpha-methyl-p-tyrosine. The lack of functional anticholinergic potency contrasted with the affinity of THD for muscarinic receptors measured as competition for [3H]QNB binding sites in striatal homogenates (Ki values: atropine, 2.7 nM; THD 14 nM; SUL, 66 nM; and MES, 90 nM). Both atropine and QNB blocked carbachol-induced inhibition of ACh release in a dose-dependent manner (IC50 values vs. 3 microM carbachol: 0.5 nM for QNB; 1.25 nM for atropine). THD, only 5 times less potent than atropine in competing for [3H]QNB binding sites, was inactive in antagonizing carbachol-induced ACh release. At very high concentrations (3-30 microM), THD, MES and SUL did enhance dopamine efflux and inhibit ACh release. In summary, the lack of effect of THD on release modulatory muscarinic receptors suggest that THD is selective for the M1 subtype. Because the M2 subtype is a small fraction of the total population in the striatum, it is not surprising that they would escape recognition in the QNB binding assays. These data suggest that inhibition of ACh release may contribute to the actions of THD only at very high doses, or when drug accumulation is abnormal.

Acetylcholine↗
PubMed1988

Amlodipine pharmacokinetics in healthy volunteers.

In the present study we investigated the pharmacokinetics and comparative bioavailability of three oral doses of amlodipine in 12 healthy male volunteers. A randomized, open-label, three period crossover study design was employed. Each subject received, on three separate occasions a single oral dose of 2.5, 5 and 10 mg amlodipine. Standing diastolic blood pressure was reduced by 1.1, 4.8 and 8 mmHg six hours after 2.5, 5 and 10 mg amlodipine, respectively. There were no significant changes in pulse rate, nor on the EKG. The curves for the mean plasma concentrations versus time for the three doses showed parallel time-courses. Highly significant positive correlations were observed between dose and AUC (0-72 hrs) and between dose and Cmax. However, dose corrected AUC and Cmax were 10-20% lower with 2.5 mg, than with 5 and 10 mg. Peak levels were achieved 5.6 to 6.4 hours postdose. Half lives were 31.2, 33 and 36.8 hours for 2.5, 5 and 10 mg respectively. Headache was the most common side effect, and was more frequently observed with the highest dose. In summary, linear relationships were found between the dose and the plasma levels of amlodipine. Decreases in standing diastolic blood pressure were also dose related. Because of its long half-life and gradual absorption, amlodipine should be effective in lowering blood pressure given once daily and the incidence of side effects due to rapid absorption should be minimized.

Adult↗